SCHEMBL3590415

SCHEMBL3590415

O=C(O)c1cc2ccccc2c(-c2ccccc2Cl)n1

nearest known ligand 0.64

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TSPO P30536 5/20 0.59
KMT2A Q03164 3/20 0.59
MEN1 O00255 2/20 0.59
ALDH1A1 P00352 2/20 0.59
CYP3A4 P08684 1/20 0.59
CYP2C9 P11712 1/20 0.59
TSHR P16473 1/20 0.59
BLM P54132 1/20 0.59
PMP22 Q01453 1/20 0.59
NR1I3 Q14994 1/20 0.59
NPSR1 Q6W5P4 1/20 0.59
CNR1 P21554 1/20 0.47
IGFBP3 P17936 2/20 0.45
KDM4E B2RXH2 1/20 0.44
GLA P06280 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31339992 1.00 TSPO (0.59) TSPOKMT2AMEN1ALDH1A1CYP3A4
SCHEMBL10984073 0.87 TSPO (0.47) TSPOKMT2AMEN1ALDH1A1CYP3A4
SCHEMBL10987170 0.87 TSPO (0.58) TSPOKMT2AMEN1ALDH1A1CYP3A4
SCHEMBL15850566 0.87 TSPO (0.61) TSPOKMT2AMEN1ALDH1A1CYP3A4
SCHEMBL10990018 0.85 KMT2A (0.50) TSPOKMT2AMEN1ALDH1A1CYP3A4
SCHEMBL3035741 0.85 KMT2A (0.46) TSPOKMT2AMEN1ALDH1A1CYP3A4
SCHEMBL3434531 0.83 TSPO (0.58) TSPOKMT2AMEN1ALDH1A1CYP3A4
SCHEMBL8470659 0.82 TSPO (0.59) TSPOKMT2AMEN1ALDH1A1CYP3A4
SCHEMBL117174 0.82 ADORA2A (0.48) TSPOKMT2AMEN1ALDH1A1CYP3A4
SCHEMBL10982335 0.82 CNR1 (0.56) TSPOKMT2AMEN1ALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101429161-A Synthesis of PET imaging agent prosome isoquinoline methanamide derivant CHANGSHU INST TECHNOLOGY (CN) 2009-05-13 CN claimed
US-20250049839-A1 COMPOSITIONS AND METHODS FOR TARGETING CELLS CHILDREN'S MEDICAL CENTER CORPORATION (US) 2025-02-13 US disclosed
US-12161663-B2 Compositions and methods for targeting cells CHILDREN'S MEDICAL CENTER CORPORATION (US) 2024-12-10 US disclosed
US-11608483-B2 Inverted culture plate system for cellular co-culture UNIVERSITY OF MARYLAND, BALTIMORE (US) 2023-03-21 US disclosed
CN-113321616-A Method for synthesizing precursor of Alzheimer's disease beta-amyloid protein deposition imaging drug 江苏华益科技有限公司 2021-08-31 CN disclosed
US-20210046105-A1 COMPOSITIONS AND METHODS FOR TARGETING CELLS CHILDREN'S MEDICAL CENTER CORPORATION (US) 2021-02-18 US disclosed
WO-2019191650-A1 COMPOSITIONS AND METHODS FOR TARGETING CELLS CHILDREN'S MEDICAL CENTER CORPORATION (US) 2019-10-03 WO disclosed
US-20190249126-A1 INVERTED CULTURE PLATE SYSTEM FOR CELLULAR CO-CULTURE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2019-08-15 US disclosed
US-9212167-B2 Mitochondrial targeted stimulators of apoptosis THE ROCKEFELLER UNIVERSITY (US) 2015-12-15 US disclosed
US-9212167-B2 Mitochondrial targeted stimulators of apoptosis THE ROCKEFELLER UNIVERSITY (US) 2015-12-15 US disclosed
WO-2008023357-A1 HETEROCYCLIC DERIVATIVES BINDING TO THE PERIPHERAL-TYPE BENZODIAZEPINE RECEPTOR (PBR) TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) 2008-02-28 WO disclosed
US-20070059230-A1 Process GLAXO GROUP LIMITED 2007-03-15 US disclosed
EP-1429783-A4 MULTI-USE MULTIMODAL IMAGING CHELATES UNIV TEXAS TECH (US) 2006-08-09 EP disclosed
EP-1663868-A2 PROCESS FOR PREPARING RADIOLABELLED COMPOUNDS GLAXO GROUP LIMITED (GB) 2006-06-07 EP disclosed
WO-2005014479-A2 PROCESS FOR PREPARING RADIOLABELED COMPOUNDS GLAXO GROUP LIMITED (GB) 2005-02-17 WO disclosed
EP-1429783-A2 MULTI-USE MULTIMODAL IMAGING CHELATES TEXAS TECH UNIVERSITY (US) 2004-06-23 EP disclosed
WO-2003020701-A9 MULTI-USE MULTIMODAL IMAGING CHELATES UNIV TEXAS TECH (US) 2003-09-12 WO disclosed
US-20030129579-A1 Formed from 1,4,7,10 tetraazacyclododecane having varying chelating ions, phosphoester chains, and light harvesting moieties. VANDERBILT UNIVERSITY 2003-07-10 US disclosed
WO-2003020701-A2 MULTI-USE MULTIMODAL IMAGING CHELATES TEXAS TECH UNIVERSITY (US) 2003-03-13 WO disclosed
US-4499094-A PREVENTION OF RESPIRATORY, UROGENITAL, CARDIOVASCULAR AND IMMUNOLOGICAL DISORDERS WHEN USING FOR BENZDIAPINES PHARMUKA LABORATOIRES (FR) 1985-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12161663-B2 Compositions and methods for targeting cells CD47, CD44, CX3CR1 TSPO 33/4885KMT2A 3252/4885MEN1 2860/4885
US-20250049839-A1 COMPOSITIONS AND METHODS FOR TARGETING CELLS CD47, CD44, CX3CR1 TSPO 33/4885KMT2A 3252/4885MEN1 2860/4885
US-20030129579-A1 Formed from 1,4,7,10 tetraazacyclododecane having varying chelating ions, phosphoester chains, and light harvesting moieties. PCNA, CLTC, PHOSPHO1 TSPO 423/4885KMT2A 2159/4885MEN1 181/4885
US-20210046105-A1 COMPOSITIONS AND METHODS FOR TARGETING CELLS CD47, CD44, CX3CR1 TSPO 33/4885KMT2A 3252/4885MEN1 2860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.